Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.
1349.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.58B
Close$
$2.11
15.2% downside
Current Fair Value
15.2% downsideOvervalued by 15.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.58 Billion |
|---|---|
| Enterprise Value | $1.37 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.14 |
| Beta | 0.09 |
| Outstanding Shares | 1,036,572,100 |
Return
| Return on Equity | -5.87% |
|---|---|
| Return on Assets | -5.23% |
| Return on Invested Capital | -5.27% |
Valuation & Multiples
| P/E Ratio | -69.72 |
|---|---|
| PEG | -8.14 |
| Price to Sales | - |
| Price to Book Ratio | 1.25 |
| Enterprise Value to Revenue | -0.37 |
| Enterprise Value to EBIT | 2.14 |
| Enterprise Value to Net Income | -11 |
| Total Debt to Enterprise | -0.07 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 17, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
October 30, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.
833 employees
CEO: Da Jun Zhao Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., along with its affiliated entities, is dedicated to the research, development, production, and commercialization of biopharmaceutical products. The company leverages its genetic eng...